Navigation Links
Beating Blood Clots after Joint Replacement
Date:2/26/2009

Building awareness and understanding among patients is key

LAS VEGAS, Feb. 26 /PRNewswire-USNewswire/ -- As the number of hip and knee replacements skyrocket into the coming years, patients and orthopaedic surgeons need to work together to evaluate and assess a potentially fatal complication -- blood clots. According to findings released today at the 2009 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) (http://www.aaos.org/), deep vein thrombosis (DVT) (http://orthoinfo.aaos.org/topic.cfm?topic=A00219) a type of prophylaxis a patient receives pre and post-joint replacement, causes controversy.

"Patients undergoing total joint replacement are at high risk for DVT and pulmonary embolism (PE), unless they receive some form of prophylaxis (http://www.aaos.org/about/papers/advistmt/1027.asp)," stated Richard J. Friedman, MD, FRCSC, Clinical Professor of Orthopaedic Surgery at the Medical University of South Carolina, and Chairman, Department of Orthopaedic Surgery, Roper Hospital, in Charleston, SC. "The type of prophylaxis a patient may receive is often tailored on an individual basis, so there is not always a 'one-size fits all method' of prophylaxis available."

  • More than 700,000 primary total hip and knee replacements are performed each year in the United States, and that number is expected to grow to over 3.5 million in 2030.

On average, about 2-3 percent of people undergoing total joint replacement (http://orthoinfo.aaos.org/topic.cfm?topic=A00233) will end up with a symptomatic DVT or PE, according to Dr. Friedman.

Currently, there are several types of prophylaxis available, and are not limited to:

  • Oral agents, like warfarin
  • Injectable agents, like low molecular weight heparins
  • Mechanical compression, sleeves on a patient's legs to help stimulate blood flow

One problem patients have with warfarin, Dr Friedman explains, "is the fact it is hard to manage the dosage and requires monitoring and dose adjustment on a regular basis. There are also many food and drug interactions that can alter the effectiveness of the drug."

"Nothing is 100 percent preventable, but we can certainly cut the risk significantly and improve compliance with options such as new pharmalogical prophylaxis, especially in terms of oral agents," stated Dr. Friedman.

He feels that symptomatic rates may be cut down even more due to more prophylaxis being oral in nature. Some of these new oral agents -- which are being considered by the Food and Drug Administration -- make it more convenient to the patient and offer tremendous potential in preventing a DVT.

Whether or not these new agents become available, the best way to arm against this problem, Dr. Friedman suggests, "is to mobilize patients as early as possible to stimulate blood flow, be sure they understand that a prophylaxis or medication must be taken and how to use it, and finally, to recognize the warning signs of a potential DVT."

Even with a thorough pre-surgical evaluation, some patients are at higher risk for DVT than others having:

  • A previous blood clot
  • A family history of blood clots
  • A genetic predisposition to blood clots, such as protein-deficient

Preventing a DVT is a complex process and as with any surgery, the patient and orthopaedic surgeon should assess what method of treatment will work for the best interest of the individual patient.

Note: This topic will be the focus of a Media Briefing entitled: "Beating Blood Clots and Deciphering DVT Prophylaxis: What the Patient Needs to Know" on Thursday, February 26, in the Sands Expo Center, Venetian Hotel, Level One, Room 904 at 9:00 AM. Panelists include: Moderator: Richard J. Friedman, MD; Paul Lachiewicz, MD; and Fred Cushner, MD.

www.orthoinfo.org

About AAOS

http://www6.aaos.org/news/Pemr/releases/release_boiler.cfm?category=40&releasenum=735

    For more information, contact:

    Lauren L. Pearson
    O (847) 384-4031
    C (224) 374-8610
    lpearson@aaos.org

    Catherine Dolf
    O (847) 384-4034
    C (847) 894-9112
    dolf@aaos.org



'/>"/>
SOURCE American Academy of Orthopaedic Surgeons
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis
2. 10-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs
3. US Testing Proves Glycn Go(TM) Increases NO in the Blood Stream
4. NicOx Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis
5. Infant Blood May Provide Insights into Diseases Present at Birth
6. Overweight Siblings of Children With Type 2 Diabetes Likely to Have Abnormal Blood Sugar Levels
7. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
8. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
9. Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion
10. Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful
11. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ORANGE COUNTY, Calif. , Oct. 10, 2017  NDS received ... Mobile  — a medical-grade battery-powered display stand specifically designed for ... aims to transform technology into a clinical solution to support the ... costs. Innovative Design ... NDS ZeroWire Mobile Wireless Solution ...
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... Milwaukee, WI (PRWEB) , ... October 13, 2017 , ... ... movement in medicine known as “patient engagement.” The patient is doing more than filling ... research partners. , “There is an increasing emphasis in health care and research ...
(Date:10/13/2017)... EDWARDSVILLE, Ill. (PRWEB) , ... ... ... University Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and ... educated healthcare professionals on guideline updates for the primary prevention of cardiovascular ...
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):